In a breakthrough for personalized cancer treatment, the USFDA has approved Promega’s OncoMate MSI Dx Analysis System, the company’s first companion diagnostic.

The test identifies endometrial cancer patients with microsatellite stable tumors who could benefit from Merck’s KEYTRUDA combined with Eisai’s LENVIMA. Experts say the approval underscores the growing power of precision diagnostics to match the right therapy to the right patient, potentially improving outcomes for those facing this challenging disease.

OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma, as per a release.

“This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with the right therapy,” says Alok Sharma, Global Clinical Market Director at Promega. “We are committed to delivering reliable tools that guide clinical decisions and help improve patient outcomes.”

The approval was supported through a collaboration with Merck, which markets KEYTRUDA plus LENVIMA in collaboration with Eisai Co., Ltd. Together, the companies are working to advance personalized medicine and expand access to diagnostics that enable informed therapeutic choices.

OncoMate MSI Dx Analysis System was previously cleared by the FDA as the first PCR-based molecular diagnostic for identifying colorectal cancer patients who may benefit from additional testing to diagnose Lynch syndrome. This approval applies to the United States and its territories. Promega MSI technology has received additional regulatory approvals in China and the European Union.